ISPC · Ispecimen Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.93M | $9.29M | $9.93M | $10.40M | $8.18M |
| Cost of Revenue | $1.71M | $5.11M | $4.82M | $4.76M | $3.59M |
| Gross Profit | $215.7K | $4.18M | $5.11M | $5.65M | $4.60M |
| R&D | - | $1.49M | $1.62M | $1.47M | $319.2K |
| SG&A | $3.47M | $6.07M | $5.94M | $6.93M | $2.40M |
| Total Operating Expenses | $10.91M | $22.02M | $21.10M | $20.59M | $10.59M |
| D&A | $1.73M | $2.29M | $117.5K | $22.4K | $44.8K |
| Operating Income | ($8.98M) | ($12.73M) | ($11.17M) | ($10.19M) | ($2.41M) |
| Interest Expense | $1.9K | $173.8K | $16.0K | $239.0K | $2.10M |
| Income Tax | - | - | $0 | $0 | $0 |
| Net Income | ($10.49M) | ($12.50M) | ($11.10M) | ($10.25M) | ($4.65M) |
| EPS - Basic | ($91.20) | ($703.20) | ($984.00) | ($928.00) | ($3976.00) |
| EPS - Diluted | ($91.20) | ($703.20) | ($984.00) | ($928.00) | ($3976.00) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $6.88M | $1.88M | $2.34M | $15.31M | $27.74M |
| Accounts Receivable | $48.3K | $1.44M | $728.4K | $1.60M | $3.00M |
| Inventory | $45.1K | - | - | - | - |
| Accounts Payable | $5.36M | $4.20M | $3.93M | $2.46M | $832.7K |
| Current Assets | $6.95M | $3.59M | $8.24M | $19.68M | $32.95M |
| Total Assets | $9.53M | $9.35M | $15.82M | $24.62M | $35.72M |
| Current Liabilities | $6.23M | $5.77M | $6.05M | $4.28M | $2.51M |
| Long-term Debt | - | - | - | - | $3.42M |
| Total Liabilities | $6.44M | $6.04M | $6.08M | $4.31M | $5.93M |
| Stockholders' Equity | $3.09M | $3.31M | $9.74M | $20.31M | $29.79M |
| Retained Earnings | ($82.35M) | ($71.86M) | ($59.36M) | ($48.27M) | ($38.02M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($4.24M) | ($8.26M) | ($5.81M) | ($5.82M) | ($288.4K) |
| Investing Cash Flow | ($1.00M) | $1.98M | ($7.23M) | ($3.19M) | ($1.10M) |
| Financing Cash Flow | $10.24M | $5.82M | $70.9K | ($3.42M) | $2.03M |
| CapEx | $454 | $31.5K | $19.5K | $215.5K | $426 |
| Free Cash Flow | ($4.24M) | ($8.30M) | ($5.83M) | ($6.03M) | ($288.8K) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 11.2% | 45.0% | 51.4% | 54.3% | 56.2% |
| Operating margin | -465.4% | -137.0% | -112.5% | -97.9% | -29.4% |
| EBITDA margin | -375.7% | -112.3% | -111.3% | -97.7% | -28.9% |
| Net margin | -543.7% | -134.5% | -111.8% | -98.5% | -56.8% |
| Free cash flow margin | -219.9% | -89.3% | -58.7% | -58.0% | -3.5% |
| FCF / Net income | 0.40 | 0.66 | 0.52 | 0.59 | 0.06 |
| R&D / Revenue | - | 16.1% | 16.3% | 14.2% | 3.9% |
| SG&A / Revenue | 180.0% | 65.3% | 59.8% | 66.6% | 29.3% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -110.0% | -133.7% | -70.2% | -41.6% | -13.0% |
| Return on equity | -339.6% | -377.5% | -113.9% | -50.4% | -15.6% |
| Return on invested capital | - | - | - | - | -5.7% |
| Liquidity | |||||
| Current ratio | 1.12 | 0.62 | 1.36 | 4.60 | 13.15 |
| Quick ratio | 1.11 | 0.62 | 1.36 | 4.60 | 13.15 |
| Cash ratio | 1.10 | 0.33 | 0.39 | 3.58 | 11.07 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | 0.11 |
| Debt / Assets | - | - | - | - | 0.10 |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -4606.4x | -73.2x | -698.0x | -42.6x | -1.1x |
| Equity multiplier | 3.09 | 2.82 | 1.62 | 1.21 | 1.20 |
| Liabilities / Assets | 0.68 | 0.65 | 0.38 | 0.18 | 0.17 |
| Efficiency | |||||
| Asset turnover | 0.20 | 0.99 | 0.63 | 0.42 | 0.23 |
| Inventory turnover | 37.98 | - | - | - | - |
| Days sales outstanding | 9d | 57d | 27d | 56d | 134d |
| Days inventory outstanding | 10d | - | - | - | - |
| Days payable outstanding | 1142d | 300d | 297d | 189d | 85d |
| Cash conversion cycle | -1124d | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 15.5x | 22.8x | 372.0x | - | - |
| P / S | 24.8x | 8.1x | 365.0x | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | -79.2% | -6.4% | -4.6% | 27.1% | - |
| Revenue CAGR (3y) | -43.0% | 4.3% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | -94.8% | -18.2% | -9.5% | 22.8% | - |
| Operating income growth (YoY) | 29.5% | -14.0% | -9.7% | -323.3% | - |
| Net income growth (YoY) | 16.1% | -12.6% | -8.3% | -120.2% | - |
| EPS growth (YoY) | 87.0% | 28.5% | -6.0% | 76.7% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 48.9% | -42.4% | 3.4% | -1989.0% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -6.7% | -66.0% | -52.0% | -31.8% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$9.93M totalProduct$9.36M · 94.3%
Shipping And Handling$566.5K · 5.7%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-9.79
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Services-Commercial Physical & Biological Research
Comparing iSpecimen Inc. against the 5 most active filers in the same SIC group.